This study is for adults 18 years or older with heart failure, a condition where the heart can't pump blood well. Participants need to have a heart function measure, called the left ventricular ejection fraction (LVEF), of 40% or more. The study tests if a drug combination, BI 690517 and empagliflozin, helps with heart failure.

Participants are randomly placed into two groups:

• BI 690517 and empagliflozin group: take both drugs daily.
• Placebo and empagliflozin group: take a placebo (inactive pill) and empagliflozin daily.

Participants stay in the study as long as it benefits them. Regular check-ups with doctors and health monitoring will occur. There is no set end date for the study. It continues until enough data is collected.

• Key Point 1: Open to adults with heart failure and LVEF of 40% or more.
• Key Point 2: No fixed study duration; individual participation depends on treatment benefit.
• Key Point 3: Participants receive regular health check-ups and may be contacted by phone.